ClinicalTrials.gg

Program

bofanglutide

Also written as “GZR18”, “GZR18 injection” and “GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Sleep Apnea, Obstructive, led by 2 companies.

Furthest: phase 3, since Dec 5, 202425 company-led studies, 9 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gan & Lee Pharmaceuticals237 open or runningphase 3since Dec 5, 2024Feb 25, 2022Jun 30, 2027phase 3 · NCT07150975
Carnot Laboratories22 open or runningphase 3since May 24, 2026May 24, 2026Oct 2027phase 3 · NCT07628985

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Feb 25, 2022.

  1. Feb 5, 20244 phase 2 studiesGan & Lee Pharmaceuticals · NCT06256562, NCT06256549, NCT06256536 and 1 more
  2. Aug 8, 20243 phase 1 studiesGan & Lee Pharmaceuticals · NCT06554054, NCT06548997, NCT06548945
  3. Oct 29, 2024Phase 1 study in Diabetes Mellitus, Type 2Gan & Lee Pharmaceuticals · NCT06670209 · 32 planned
  4. Dec 5, 2024Phase 3 study in ObesityGan & Lee Pharmaceuticals · NCT06728124 · 640 enrolled · China
  5. Dec 16, 2024Phase 2 study in ObesityGan & Lee Pharmaceuticals · NCT06737042 · 326 enrolled · United States
  6. Jan 3, 20252 phase 3 studies in Diabetes Mellitus, Type 2Gan & Lee Pharmaceuticals · NCT06778967, NCT06777238
  7. Jun 27, 2025Phase 2 study in Diabetes Mellitus, Type 2Gan & Lee Pharmaceuticals · NCT07055386 · 90 enrolled · China
  8. Jul 9, 2025Phase 1 study in OverweightGan & Lee Pharmaceuticals · NCT07119450 · 6 enrolled · China
  9. Aug 6, 20253 phase 1 studies in ObesityGan & Lee Pharmaceuticals · NCT07128888, NCT07141030, NCT07144098
  10. Aug 27, 2025Phase 3 study in ObesityGan & Lee Pharmaceuticals · NCT07150975 · 420 planned · China
  11. Nov 20, 2025Phase 3 study in OverweightGan & Lee Pharmaceuticals · NCT07292441 · 224 enrolled · China
  12. Jan 5, 2026Phase 1 study in Obesity&T2DGan & Lee Pharmaceuticals · NCT07355738 · 266 enrolled · China
  13. Mar 20, 20262 phase 3 studies in Sleep Apnea, ObstructiveGan & Lee Pharmaceuticals · NCT07493057, NCT07501832
  14. May 24, 2026Carnot Laboratories's first studies: 2 phase 3 studiesNew to Carnot LaboratoriesCarnot Laboratories · NCT07628985, NCT07622810

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in ObesityGan & Lee Pharmaceuticals · NCT07150975
  2. Oct 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2Carnot Laboratories · NCT07628985
  3. Nov 14, 2027Primary completion: phase 3 study in Sleep Apnea, ObstructiveGan & Lee Pharmaceuticals · NCT07493057
  4. Dec 2027Primary completion: phase 3 study in ObesityCarnot Laboratories · NCT07622810

TargetBeta

GLP1R →read by rule
“Bofanglutide (GZR18) is a long-acting GLP-1 receptor agonist administered by subcutaneous injection every 2 weeks.”study text, by rule · the study

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319
efpeglenatideruleHanmi Pharmaceuticalphase 313

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07628985Diabetes Mellitus, Type 2 · Mexico3Not yet recruitingCarnot LaboratoriesOct 2027374
NCT07622810Obesity · Mexico3Not yet recruitingCarnot LaboratoriesDec 2027352
NCT07501832Sleep Apnea, Obstructive · China3RecruitingGan & Lee PharmaceuticalsSep 28, 2028140
NCT07493057Sleep Apnea, Obstructive · China3RecruitingGan & Lee PharmaceuticalsNov 14, 2027140
NCT07355738Obesity&T2D · China1CompletedGan & Lee PharmaceuticalsMay 22, 2026266
NCT07292441Overweight · China3CompletedGan & Lee PharmaceuticalsSep 22, 2026224
NCT07150975Obesity · China3RecruitingGan & Lee PharmaceuticalsJun 30, 2027420
NCT07144098Obesity · China1CompletedGan & Lee PharmaceuticalsApr 7, 202624
NCT07141030Obesity · China1CompletedGan & Lee PharmaceuticalsOct 20, 202532
NCT07128888Obesity · China1CompletedGan & Lee PharmaceuticalsApr 13, 202660
NCT07119450Overweight · China1CompletedGan & Lee PharmaceuticalsAug 13, 20256
NCT07055386Diabetes Mellitus, Type 2 · China2Active, not recruitingGan & Lee PharmaceuticalsJun 28, 202690
NCT06777238Diabetes Mellitus, Type 2 · China3CompletedGan & Lee PharmaceuticalsJul 30, 2026274
NCT06778967Diabetes Mellitus, Type 2 · China3CompletedGan & Lee PharmaceuticalsSep 18, 20261,133
NCT06737042Obesity · United States2CompletedGan & Lee PharmaceuticalsFeb 27, 2026326
NCT06728124Obesity · China3CompletedGan & Lee PharmaceuticalsMar 26, 2026640
NCT06670209Diabetes Mellitus, Type 21Not yet recruitingGan & Lee PharmaceuticalsMar 19, 202532
NCT06554054Diabetes Mellitus, Type 2 · China1Active, not recruitingGan & Lee PharmaceuticalsDec 9, 202492
NCT06548997Diabetes Mellitus, Type 2 · China1CompletedGan & Lee PharmaceuticalsOct 20, 202257
NCT06548945Overweight · China1CompletedGan & Lee PharmaceuticalsAug 14, 202316
NCT06256562Obesity · China2CompletedGan & Lee PharmaceuticalsJun 5, 2024340
NCT06256549Diabetes Mellitus, Type 2 · China2Active, not recruitingGan & Lee PharmaceuticalsJul 20, 2024272
NCT06256536Obesity · China2CompletedGan & Lee PharmaceuticalsOct 22, 202360
NCT06256523Diabetes Mellitus, Type 2 · China2CompletedGan & Lee PharmaceuticalsSep 28, 202372
NCT05328726Diabetes Mellitus, Type 2 · United States1CompletedGan & Lee PharmaceuticalsFeb 9, 202324

How it is read

Names in the registry

  • “GZR18”, 13 entries
  • “GZR18 injection”, 8 entries
  • “GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets”, 1 entry
  • “GZR18 injection A”, 1 entry
  • “GZR18 injection B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.